Pregnancy outcomes after exposure to azithromycin
Author Information
Author(s): Sarkar Moumita, Woodland C Cindy, Koren Gideon, Einarson Adrienne RN
Primary Institution: The Hospital for Sick Children, Toronto, Canada
Hypothesis
Is there an increased risk of major malformations in women exposed to azithromycin during pregnancy?
Conclusion
Gestational exposure to azithromycin is not associated with an increase in the rate of major malformations above the baseline of 1–3%.
Supporting Evidence
- Rates of major malformations were 3.4% in the azithromycin group compared to 2.3% in the disease-matched group and 3.4% in the non-teratogen group.
- 88% of women in the azithromycin group took the drug during the first trimester.
- The study included 123 women in each of the three groups.
Takeaway
This study looked at pregnant women who took azithromycin and found that it doesn't seem to cause more birth defects than normal.
Methodology
Pregnant women were divided into three groups: those who took azithromycin, those who took other antibiotics, and those who took non-teratogenic agents, and outcomes were compared.
Potential Biases
Potential bias from relying on maternal reports for outcomes.
Limitations
The study had a small sample size, limiting its power to detect rare malformations.
Participant Demographics
Pregnant women, with a focus on those taking azithromycin for respiratory infections and chlamydia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website